Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LXEO

Lexeo Therapeutics Inc

Oct 27 • 09:48AM ET

9.61

+0.38 4.15 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP QURE SRPT NTLA BEAM RARE BLUE EDIT SGMO ADVM

| Held by: VTI IWM VXF IBB IWN DFAS DFAC VTWO ITOT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.26	Insider Own	21.20%	Shs Outstand	54.00M	Perf Week	4.26%
Market Cap	519.11M	Forward P/E	-	EPS next Y	-2.00	Insider Trans	-0.31%	Shs Float	42.55M	Perf Month	41.99%
Enterprise Value	395.13M	PEG	-	EPS next Q	-0.52	Inst Own	69.34%	Short Float	17.19%	Perf Quarter	134.46%
Income	-114.17M	P/S	-	EPS this Y	18.77%	Inst Trans	0.48%	Short Ratio	8.93	Perf Half Y	170.79%
Sales	0.00M	P/B	3.76	EPS next Y	20.27%	ROA	-62.04%	Short Interest	7.32M	Perf YTD	46.09%
Book/sh	2.56	P/C	3.91	EPS next 5Y	15.54%	ROE	-75.32%	52W High	11.72 -17.98%	Perf Year	-1.81%
Cash/sh	2.46	P/FCF	-	EPS past 3/5Y	-17.65% -99.98%	ROIC	-79.03%	52W Low	1.45 562.97%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.14% 7.64%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-20.53%	Oper. Margin	-	ATR (14)	0.64	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	72.09	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	4.43	EPS Q/Q	6.90%	SMA20	16.06%	Beta	1.63	Target Price	19.56
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	48.73%	Rel Volume	2.11	Prev Close	9.23
Employees	72	LT Debt/Eq	0.05	Earnings	Aug 14 BMO	SMA200	112.92%	Avg Volume	819.36K	Price	9.61
IPO	Nov 03, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.69% -	Trades		Volume	162,042	Change	4.15%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-25	Initiated	Guggenheim	Buy	$30
Jul-31-25	Initiated	Oppenheimer	Outperform	$20
Jun-13-24	Initiated	Robert W. Baird	Outperform	$28
Jun-06-24	Initiated	H.C. Wainwright	Buy	$22
Nov-28-23	Initiated	Stifel	Buy	$20
Nov-28-23	Initiated	RBC Capital Mkts	Outperform	$22
Nov-28-23	Initiated	Leerink Partners	Outperform	$19
Nov-28-23	Initiated	JP Morgan	Overweight	$20
Nov-28-23	Initiated	Chardan Capital Markets	Buy	$23

Oct-26-25 06:05AM	Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise (Insider Monkey)
Oct-23-25 09:55AM	Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High? (Zacks)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-20-25 04:05PM	Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering (GlobeNewswire)
Oct-17-25 09:27AM	Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 (Insider Monkey) +9.24%
11:29PM	Loading…
Oct-16-25 11:29PM	Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement (GlobeNewswire)
04:32PM	Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-07-25 06:00AM	Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +28.90%
Aug-14-25 07:30AM	Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
Jul-31-25 09:46AM	Meta, Microsoft upgraded: Wall Street's top analyst calls (The Fly)
Jul-29-25 10:23AM	Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) (Insider Monkey)
Jul-07-25 07:00AM	Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia (GlobeNewswire)
Jun-24-25 07:30AM	Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics (GlobeNewswire) +6.31%
May-27-25 07:31AM	Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases (GlobeNewswire)
07:00AM	Loading…
May-12-25 07:00AM	Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
May-05-25 02:19PM	Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (Seeking Alpha)
May-01-25 09:16AM	Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire) +19.85%
Apr-07-25 06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study (GlobeNewswire) -23.34%
Mar-25-25 09:10AM	Pharma Frenzy: Volatility Ignites Biotech Sector (MarketBeat) +8.56%
08:44AM	Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? (Insider Monkey)
Mar-24-25 07:00AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (GlobeNewswire) +50.92%
Jan-07-25 07:30AM	Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 07:00AM	Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer (GlobeNewswire) -5.03%
Dec-02-24 07:00AM	Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024 (Business Wire)
Nov-13-24 07:30AM	Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 06:14AM	Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) -17.00%
Oct-22-24 07:30AM	Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference (GlobeNewswire)
Sep-05-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 07:00AM	Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
11:03AM	Loading…
Jul-16-24 11:03AM	Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data (Zacks)
Jul-15-24 04:17PM	Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion (Investor's Business Daily) -26.08%
10:11AM	Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout (Investor's Business Daily)
06:36AM	Lexeo gene therapy shows signs of heart benefit in small study (BioPharma Dive)
06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire)
Jul-11-24 08:00AM	Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024 (GlobeNewswire) +6.08%
Jul-08-24 07:00AM	Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors (GlobeNewswire) +5.55%
May-14-24 12:00PM	What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet (Zacks)
May-09-24 07:00AM	Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire) +5.69%
May-07-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-22-24 07:30AM	Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +5.06%
Apr-16-24 07:30AM	Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy (GlobeNewswire)
Mar-13-24 04:22PM	Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing (GlobeNewswire) +5.67% -5.43%
Mar-11-24 07:42AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
07:30AM	Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing (GlobeNewswire)
Feb-05-24 07:00AM	Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments (GlobeNewswire)
Jan-03-24 07:00AM	Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (GlobeNewswire) +8.71%
Dec-13-23 04:59AM	Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs (GuruFocus.com)
Dec-11-23 12:05PM	LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 (InvestorPlace) -12.94%
07:00AM	Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks)
Nov-02-23 09:51PM	Lexeo Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
See Tai Sandi	Chief Development Officer	Oct 17 '25	Sale	8.94	3,888	34,767	65,862	Oct 17 07:29 PM
Robertson Jenny	Chief Legal Officer	Oct 17 '25	Sale	8.94	3,526	31,530	68,930	Oct 17 07:28 PM
Otero Jose Manuel	Chief Technical Officer	Oct 17 '25	Sale	8.94	2,115	18,913	64,197	Oct 17 07:28 PM
Adler Eric	Chief Medical Officer	Oct 17 '25	Sale	8.94	3,382	30,242	73,261	Oct 17 07:26 PM
Townsend Richard Nolan	Chief Executive Officer	Oct 17 '25	Sale	8.94	13,133	117,436	242,118	Oct 17 07:26 PM
Adler Eric	Officer	Oct 17 '25	Proposed Sale	8.94	3,382	30,242		Oct 17 04:30 PM
Otero Jose Manuel	Officer	Oct 17 '25	Proposed Sale	8.94	2,115	18,913		Oct 17 04:15 PM
Robertson Jenny	Officer	Oct 17 '25	Proposed Sale	8.94	3,526	31,530		Oct 17 04:14 PM
Townsend Richard Nolan	Officer	Oct 17 '25	Proposed Sale	8.94	13,133	117,437		Oct 17 04:10 PM
See Tai Sandi	Officer	Oct 17 '25	Proposed Sale	8.94	3,888	34,767		Oct 17 04:08 PM
Otero Jose Manuel	Chief Technical Officer	Aug 18 '25	Sale	4.67	2,848	13,294	60,372	Aug 20 05:05 PM
Robertson Jenny	Chief Legal Officer	Aug 18 '25	Sale	4.67	542	2,530	62,556	Aug 20 05:03 PM
Adler Eric	Chief Medical Officer	Aug 18 '25	Sale	4.67	608	2,838	67,073	Aug 20 05:02 PM
Townsend Richard Nolan	Chief Executive Officer	Aug 18 '25	Sale	4.67	2,735	12,767	220,058	Aug 20 05:00 PM
See Tai Sandi	Chief Development Officer	Aug 18 '25	Sale	4.67	382	1,783	58,860	Aug 20 04:58 PM
Otero Jose Manuel	Officer	Aug 18 '25	Proposed Sale	4.67	2,848	13,295		Aug 18 03:31 PM
Adler Eric	Officer	Aug 18 '25	Proposed Sale	4.67	608	2,838		Aug 18 03:26 PM
Townsend Richard Nolan	Officer	Aug 18 '25	Proposed Sale	4.67	1,115	5,205		Aug 18 03:24 PM
See Tai Sandi	Officer	Aug 18 '25	Proposed Sale	4.67	382	1,783		Aug 18 03:20 PM
Robertson Jenny	Officer	Aug 18 '25	Proposed Sale	4.67	542	2,530		Aug 18 03:18 PM
Townsend Richard Nolan	Chief Executive Officer	May 16 '25	Sale	2.77	1,074	2,979	221,173	May 20 05:00 PM
Adler Eric	Chief Medical Officer	May 16 '25	Sale	2.77	585	1,623	67,681	May 20 05:00 PM
Robertson Jenny	Chief Legal Officer	May 16 '25	Sale	2.77	521	1,445	63,098	May 20 05:00 PM
See Tai Sandi	Chief Development Officer	May 16 '25	Sale	2.77	367	1,018	59,242	May 20 05:00 PM
Townsend Richard Nolan	Officer	May 16 '25	Proposed Sale	2.77	1,074	2,980		May 16 03:51 PM
Robertson Jenny	Officer	May 16 '25	Proposed Sale	2.77	521	1,445		May 16 03:41 PM
See Tai Sandi	Officer	May 16 '25	Proposed Sale	2.77	367	1,018		May 16 03:36 PM
Adler Eric	Officer	May 16 '25	Proposed Sale	2.77	585	1,623		May 16 03:35 PM
Townsend Richard Nolan	Chief Executive Officer	Feb 19 '25	Sale	4.41	4,326	19,091	220,119	Feb 21 05:10 PM
See Tai Sandi	Chief Development Officer	Feb 19 '25	Sale	4.41	1,486	6,558	53,889	Feb 21 05:09 PM
Adler Eric	Chief Medical Officer	Feb 19 '25	Sale	4.41	2,359	10,410	68,266	Feb 21 05:09 PM
Robertson Jenny	Chief Legal Officer	Feb 19 '25	Sale	4.41	2,101	9,272	57,899	Feb 21 05:08 PM
Townsend Richard Nolan	Officer	Feb 19 '25	Proposed Sale	4.41	4,326	19,091		Feb 19 04:25 PM
Robertson Jenny	Officer	Feb 19 '25	Proposed Sale	4.41	2,101	9,272		Feb 19 04:19 PM
See Tai Sandi	Officer	Feb 19 '25	Proposed Sale	4.41	1,486	6,558		Feb 19 04:15 PM
Adler Eric	Officer	Feb 19 '25	Proposed Sale	4.41	2,359	10,410		Feb 19 04:06 PM
Townsend Richard Nolan	Chief Executive Officer	Dec 10 '24	Option Exercise	2.33	2,500	5,825	123,195	Dec 12 05:00 PM
Townsend Richard Nolan	Chief Executive Officer	Dec 10 '24	Sale	8.20	2,500	20,491	120,695	Dec 12 05:00 PM
Richard Nolan Townsend	Director	Dec 10 '24	Proposed Sale	8.24	2,500	20,600		Dec 10 05:18 PM
CHOLMONDELEY PAULA H	Director	Nov 25 '24	Buy	6.99	15,000	104,852	30,627	Nov 26 05:00 PM
Townsend Richard Nolan	Chief Executive Officer	Nov 11 '24	Option Exercise	2.33	2,500	5,825	123,195	Nov 13 05:33 PM
Townsend Richard Nolan	Chief Executive Officer	Nov 11 '24	Sale	7.82	2,500	19,557	120,695	Nov 13 05:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXEO

Lexeo Therapeutics Inc

Upgrade your FINVIZ experience